Criteria for deciding cost-effectiveness for expensive new anti-cancer agents.
dc.contributor.author | Sarin, Rajiv | en_US |
dc.date.accessioned | 2008-01-18 | en_US |
dc.date.accessioned | 2009-06-01T16:27:54Z | |
dc.date.available | 2008-01-18 | en_US |
dc.date.available | 2009-06-01T16:27:54Z | |
dc.date.issued | 2008-01-18 | en_US |
dc.identifier.citation | Sarin R. Criteria for deciding cost-effectiveness for expensive new anti-cancer agents. Journal of Cancer Research and Therapeutics. 2008 Jan-Mar; 4(1): 1-2 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/111571 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.cancerjournal.net | en_US |
dc.subject.mesh | Antineoplastic Agents --economics | en_US |
dc.subject.mesh | Cost-Benefit Analysis | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Neoplasms --drug therapy | en_US |
dc.title | Criteria for deciding cost-effectiveness for expensive new anti-cancer agents. | en_US |
dc.type | Editorial | en_US |
Files
License bundle
1 - 1 of 1